SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ — Volcano
Corporation (Nasdaq: VOLC), a leading developer and manufacturer of
precision intravascular therapy guidance tools designed to enhance
the diagnosis and treatment of coronary and peripheral vascular
disease, said today that it will be participating in the 30th
Annual Canaccord Genuity Growth Conference on Tuesday, August 10.
The presentation by Scott
Huennekens, president and chief executive officer, will
begin at 9 a.m., Eastern Daylight
Time (6 a.m., Pacific Daylight
The presentation will be available through the conference
website at http://www.wsw.com/webcast/canaccord2/volc/
and via the company’s website at www.volcanocorp.com.
Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to
facilitate endovascular procedures, enhance the diagnosis of
vascular and structural heart disease and guide optimal therapies.
The company’s intravascular ultrasound (IVUS) product line includes
consoles that can be integ